strong and effective management team, narrowed the focus of Aderis’ research investments to programs with clear commercial promise, completed a $45 million private placement at a substantial uptick in value and led the revitalization of relationships with three corporate partners, one of whom ultimately purchased the company’s primary assets at a profit to the investors, founders and employees.
Mr. Savas joined (publicly traded) Alseres Pharmaceutical as its chairman and chief executive officer in September 2004. His mission was to realize value from the company’s portfolio of assets. He again assembled a strong board of directors, scientific advisors and management in order to rationalize the company’s new product development pipeline. The company successfully turned around its relationship with the Imaging Division of the FDA and subsequently obtained a landmark Special Protocol Agreement for the development and approval of its lead product, Altropane. The company is currently in advanced discussions with potential development, manufacturing and commercialization partners.
Mr. Savas earned his BA in chemistry from Syracuse University in 1975 and lives in the greater Boston area with his wife and six children.
Full biographies, unique experience, expertise & accomplishments of each advisory board member:
- Neil J. Campbell,
M.A., M.B.A. – Chairman - Kevin Carroll
- Edward L. Erickson
- Daniel D'Agostino
- Nigel Gaymond, M.A.
- David M. Koeninger
- Udo Klein, Ph.D.
- Stefan Loren, Ph.D.
- Kevin Nickels
- Rick Pierce
- Robin Pratt, Ph.D.
- Linda M. Pullan, Ph.D.
- Dane Saglio, C.P.A.
- Peter G. Savas
- Chris Ward
- Ruth Williams, Esq.
Peter G. Savas began his career as a senior research scientist at Bristol-Myers in Syracuse, New York. After five years at Bristol-Myers, he joined Waters Associates to pursue a career as a business leader. He rose quickly through the ranks of Waters having distinguished himself amongst his peers with strong technical, management and leadership skills. His impact on the performance and quality of the company’s marketing, sales and service operations led to double digit growth in revenues and profits. Following the acquisition of Waters by Millipore Corporation, Mr. Savas was appointed General Manager of Millipore’s wholly owned Continental Water Systems Corporation. He again delivered double digit growth in revenues and profits, which led to its subsequent acquisition. From 1984 through 1999, Mr. Savas applied his business and financial leadership skills to the turnaround and subsequent sale of four companies specializing in diagnostic devices, laboratory automation, production equipment and contract bio-manufacturing services.
In September 2000, Mr. Savas was named president and chief executive officer of Aderis Pharmaceuticals, a privately held biotech company headquartered in Hopkinton, Massachusetts. At Aderis, he assembled a world-class board of directors and was subsequently elected Chairman. He attracted respected scientific advisors including two Nobel Laureates, assembled a st
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||